LGALS9 and neoplasm: Here, Gal-9 was firstly evidenced with much higher expression on the primary solid tumors than such as CD80/86 (B7) and PD-L1 (CD274) as well, which suggests that Gal-9 may be a key factor in inhibiting the anti-tumor immunity.